abstract |
The present invention relates to a compound, which specifically binds to CD38, for use as a medicament in the prevention and/or treatment of a neurodegenerative disease and/or an inflammatory disease, by the opening of NAADP receptors Two Pore Channels TPC and/or TPC2, wherein said compound activates the opening of NAADP receptors Two Pore Channels TPC1 and/or TPC2. |